Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.
Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Headaches in multiple sclerosis: Cross-sectional study of a multiethnic population.
Episode 12 with Professor Gavin Giovannoni on the potential for finding a cure for MS.
Meta-analysis of adverse events in recent randomized clinical trials for dimethil fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis.
US and EU regulatory authorities accept oral BG-12 marketing applications for review
Neuroprotective effects of resident microglia following acute brain injury.
Glial Biology: Functional Interactions Among Glia & Neurons (Gordon Research Seminar)
Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis (TENERE)
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Episode 18 with Dr. Samuel Ludwin on new approaches to remyelination therapies.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
The Brain as a Target of Inflammatory Processes
Episode 8 with Dr. Wendy Macklin on myelination and the zebrafish model of MS
Clinical Characteristics of Pediatric-Onset and Adult-Onset Multiple Sclerosis in Hispanic Americans.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Serum IL-33 levels and skin mRNA expression in Behçet's disease.
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study.
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.
Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.

Pages